CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock News

USA - NASDAQ:CNTB - US2075231017 - Common Stock

1.49 USD

+0.1 (+7.19%)

Last: 10/3/2025, 8:00:01 PM

1.5001 USD

+0.01 (+0.68%)

Pre-Market: 10/6/2025, 8:00:02 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CNTB Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Benzinga - Mentions: BOLT SCLX TSHA RVPH ...

12 Health Care Stocks Moving In Thursday's Intraday Session

7 days ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

7 days ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

a month ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

a month ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

a month ago - By: Benzinga - Mentions: AEMD CHEK WVE SSKN ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a month ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

a month ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

a month ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

2 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

2 months ago - By: The Motley Fool

Connect Biopharma Posts Q2 Revenue Drop

2 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

3 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

4 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

5 months ago - By: Connect Biopharma Holdings Limited

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma